Navigation Links
Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
Date:1/31/2008

NEW YORK, Jan. 31 /Xinhua-PRNewswire-FirstCall/ -- Max Nutrition Inc. (OTC Bulletin Board: MXNU; the "Company") announced today that the Company has completed the share exchange (the "Closing") pursuant to an Agreement and Plan of Reorganization with American Spring Pharmaceutical, Inc., a Delaware corporation ("ASPI"). Pursuant to the Agreement, ASPI transferred 100% of the issued and outstanding shares of Gansu Biology Science and Technology Stock Co., Ltd ("GDBS") to the Company in exchange for 20,000,000 shares of the Company's common stock.

All of the present officers and directors of the Company resigned and Mr. Qi Jinjun, the Chairman and CEO of GDBS, became the sole officer and director of the Company.

"The completion of the share exchange is a great milestone in the development of GDBS; it symbolizes the first step of GDBS to become a truly global player in the fertilizer additive and livestock feed market," remarked Mr. Qi Jinjun. "In the future, we will continue to work hard and reaffirm our commitment to providing high quality fertilizer additives and animal feed for agricultural use."

ASPI, through its wholly owned operating subsidiary Gansu Dasheng Biology Science and Technology Stock Co., Ltd. (GDBS), a limited liability corporation organized under the laws of the People's Republic of China ("PRC"), engages in the development, production and distribution of additives for fertilizers and animal feed that have been enhanced through the addition of bacteria.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

Peter D. Zhou

Tel: +1-212-232-0120


'/>"/>
SOURCE Max Nutrition, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Healionics Corporation Completes Series A Financing
2. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
3. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
4. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
5. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
6. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
7. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. China Medical Technologies Completes Acquisition of BBE
9. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
10. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
11. Pharmos Corporation Completes Initial Closing of Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... May 23, 2017 As Ebola resurfaces in the ... deaths and 20 suspected cases now reported, a new analysis ... database, showed a correlation between the 2014 and 2017 outbreaks ... rose sharply in 2012-13, which preceded the 2014 outbreak. An ... Ebola gene Replikin counts in 2014-15, which again precedes the ...
(Date:5/23/2017)... ... 22, 2017 , ... NetDimensions has been ranked as a ... for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who possess ... against those strategies. NetDimensionsā€™ ranking as a Leader due to its strengths in: ...
(Date:5/23/2017)... ... 2017 , ... Bacterial biofilms, surface adherent communities of bacteria that are encased ... food poisoning and catheter infections to gum disease and the rejection of medical implants. ... dollars per year, there is currently a paucity of means for preventing their formation ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics and pathology ... B2 at the Association for Pathology Informatics Annual Summit at the ... demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):